Celiprolol: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: March 6, 2026🚩 Report this page

Celiprolol

Beta Blocking Agents, Selective

GB MHRA

Drug class: Beta Blocking Agents, Selective
Availability: See label
Markets covered: 1
Products on record: 9

Overview

Celiprolol is an active pharmaceutical ingredient in the Beta Blocking Agents, Selective group (C07AB). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	9	March 6, 2026

GBUnited Kingdom· MHRA

9 products

Uses

GBOfficial regulatory label· revised March 6, 2026[1]

The management of mild to moderate hypertension.

How to take

GBOfficial regulatory label

Sources & citations

[1]MHRA (UK) · PL450430027 · revised March 6, 2026

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised March 6, 2026[1]

Adverse drug reactions are listed below by system organ class and frequency.
Frequencies are defined as:
Very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000), not known (cannot be estimated from the available data). Beta-blockers may mask the symptoms of thyrotoxicosis or hypoglycaemia (in particular, tachycardia).
5) Psychiatric disorders: Common: depression Uncommon: insomnia Not known: libido decrease, hallucination, nightmare Confusion and psychoses have also been reported.
Nervous system disorders:
Common: tremor, paraesthesia, headache, asthenia, somnolence, dizziness Eye disorders: Not known: xerophthalamias, impaired vision Cardiac disorders: Uncommon: palpitations Not known: bradycardia, syncope, cardiac failure and arrhythmias (including slowed A-V conduction and in susceptible patients there may be precipitation of existing A-V block).
4) Uncommon: hypotension, peripheral coldness Respiratory, thoracic and mediastinal disorders: Uncommon: dyspnoea Not known: bronchospasm (in patients with bronchial asthma or with a history of bronchial complaints) and interstitial pneumonitis Gastrointestinal disorders: Common: vomiting, nausea, abdominal pain, dry mouth Not known: diarrhoea Skin and subcutaneous tissue disorders: Common: hyperhidrosis, erythema, rash, pruritus Not known: dermatitis psoriasiform, aggravation of psoriasis, alopecia Musculoskeletal and connective tissue disorders: Uncommon: muscle spasms Not known: systemic lupus erythematosus, arthralgia Reproductive system and breast disorders: Common: erectile dysfunction Investigations: Common: increase in antinuclear antibodies (ANAs) Not known: hepatic transaminases increased Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised March 6, 2026[1]

Asthma and bronchospastic diseases Although cardio selective beta-blockers may have less effect on lung function than non-selective beta-blockers, as with all beta-blockers these should be avoided in patients with chronic obstructive airways disease, and in patients with a history of bronchospasm or bronchial asthma, unless there are compelling clinical reasons for their use.
Where such reasons exist, celiprolol may be used but with the utmost caution under specialist supervision.
The label will carry the following warning:
Do not take this medicine if you have wheezing or asthma. Impaired renal and hepatic function Celectol may be used in patients with mild to moderate degrees of reduced renal function as celiprolol is cleared by both renal and non-renal excretory pathways.
A reduction in dosage by half may be appropriate in patients with creatinine clearances in the range of 15 – 40 ml per minute. However, careful surveillance of such patients is recommended until steady state blood levels are achieved which typically would be within one week.
Celectol is not recommended for patients with creatinine clearance less than 15 ml per minute. Patients with hepatic impairment should also be carefully monitored after commencing therapy and a reduced dosage should be considered. Withdrawal In patients with coronary insufficiency, treatment should not be discontinued abruptly.
Sudden withdrawal of beta-blockers in patients with ischaemic heart disease may result in the appearance of anginal attacks of increased frequency or severity or deterioration in cardiac state. Although no adverse effects due to abrupt cessation of Celectol have been seen in clinical trials, therapy should be gradually reduced over 1 – 2 weeks, at the same time, if necessary, initiating replacement therapy to prevent exacerbation of angina pectoris.
General anaesthesia Celectol therapy must be reported to the anaesthetist prior to general anaesthesia. If it is decided to withdraw the drug before surgery, 48 hours should be allowed to elapse between the last dose and anaesthesia.
5). In the event of continuation of Celectol treatment special care should be exercised when using anaesthetic agents such as ether, cyclopropane or trichloroethylene. The patient may be protected against vagal reactions by the intravenous administration of atropine.

This is not medical advice. Consult a qualified healthcare professional.

Overview

Regulatory status by market

GBUnited Kingdom· MHRA

Drugs in the same class

Sources & citations